MetaVia (MTVA) Gains from Investment Securities (2023 - 2026)
MetaVia's (MTVA) quarterly Gains from Investment Securities came in at -$31000.0 in Q4 2025, up 84.73% YoY from -$16781.3 in Q4 2024, and down 158.49% on a QoQ basis from $53000.0 in Q3 2025.
MetaVia (MTVA) Gains from Investment Securities (2023 - 2026) Analysis & Trends
MetaVia (MTVA) has 3 years of Gains from Investment Securities data on file, last reported at -$31000.0 in Q4 2025.
- Quarterly Gains from Investment Securities rose 84.73% year-over-year to -$31000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$225000.0 (up 24.24% YoY) and the FY2025 annual result came in at -$225000.0, up 24.24% from the prior year.
- Gains from Investment Securities declined to -$31000.0 in Q4 2025, from $53000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $133000.0 in Q2 2024 to a low of -$3.1 million in Q2 2023.
- A 3-year average of -$289750.0 and a median of -$42500.0 in 2023 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities plunged 441.38% — and 2025, when it jumped 117.85%.
- Tracing MTVA's Gains from Investment Securities over 3 years: stood at -$54000.0 in 2023, then plunged by 275.93% to -$203000.0 in 2024, then jumped by 84.73% to -$31000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$31000.0 (Q4 2025), $53000.0 (Q3 2025), and -$160000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,000.00 |
| Jun 30, 2026 | 4,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Jun 30, 2025 | -160,000.00 |
| Jun 30, 2025 | -160,000.00 |
| Mar 31, 2025 | -87,000.00 |
| Mar 31, 2025 | -87,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Sep 30, 2024 | -297,000.00 |
| Sep 30, 2024 | -297,000.00 |
| Jun 30, 2024 | 133,000.00 |
| Jun 30, 2024 | 133,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | -54,000.00 |
| Dec 31, 2023 | -54,000.00 |